Geron (GERN)
(Delayed Data from NSDQ)
$4.60 USD
+0.04 (0.88%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $4.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Geron Corporation [GERN]
Reports for Purchase
Showing records 41 - 60 ( 245 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Positive Topline IMerge Phase 3 Results Support Potential for MDS Disease Modification; Reit. Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
IMerg-ing Highly Impressive; Increasing PT to $6
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Impressive Long Term Follow-up Data from Ph 2 Data Highlighted at ASH
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
LT Imetelstat Data Provide Strong Evidence of Disease Modification; Reit Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Imetelstat Set to Emerge as an Important New MDS Treatment Option in 2023; Reiterate Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; ASH Updates Ahead; Ph 3 LR-MDS Topline in January
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $5 PT: Exposing the Ends, with the End in Sight
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis; Reiterate Buy Rating and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
IMerge Phase 3 Top-Line Data on Track For Early January 2023; Reiterate Buy Rating and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
IMerge Phase 3 Top-Line Results Expected in Early January 2023; Reiterate Buy Rating and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Steady Imetelstat Progress Continues into 2022; Reiterate Buy Rating and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Expecting Imetelstat Clinical Programs to Make Steady Progress in 2022; Reiterate Buy Rating and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Imetelstat Phase 3 Trials on Track and Three New Clinical Programs Unveiled
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Survival Comparison Favors Imetelstat Versus Real World Data; Reiterate Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V